Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImaginAb partners with Eurogentec
The tie up is expected to accelerate the development of ImaginAb’s pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.
The tie up is expected to accelerate the development of ImaginAb’s pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.
The company’s decision follows positive results from Phase 1/2 clinical study of AST-915 which showed that the drug is safe and well tolerated and demonstrated a clear effect
Pre-clinical data shows that this compound is a potent suppressor of angiogenesis, an established approach in anti-cancer treatment. The primary objective of the trial is to determine the
For the second quarter of 2010, the company has generated net income of $16.83m, compared to $3.45m for the same period in 2009. Parexel’s income from operations was
Aurobindo Pharma‘s Famciclovir tablets 125mg, 250mg and 500mg are the generic version of Novartis Pharmaceuticals’ Famvir tablets 125mg, 250mg and 500mg and is indicated for the treatment of
Upon closing, PharmaSwiss is expected to have approximately EUR38m cash on hand and no debt. Following the acquisition, the senior management team of PharmaSwiss will remain with Valeant
The first, a Phase 2a study, will evaluate VB-111 in patients with advanced differentiated thyroid cancer (DTC), while the second trial, a Phase 1/2 trial, will evaluate VB-111
The randomised, double-blind, placebo-controlled, dose escalation study will be conducted at one centre in the US and is designed to enroll 65 subjects in eight dose cohorts. The
Prior to Nuvilex, Ryan worked as the CEO of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management,
Nuedexta is a combination of two components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling